£199.99 £139.99 for one year of Unlimited learning. Offer ends on 14 November 2022 at 23:59 (UTC). T&Cs apply

Find out more
EGFR and tumor cells
Skip main navigation

EGFR and tumor cells

EGFR and tumor cells

Binding of EGFR to its cognate ligands leads to autophosphorylation of the receptor itself by the tyrosine kinase activity.

A variety of signal transduction pathways are subsequently activated, which are involved in regulating cellular proliferation, differentiation, and survival.

Although EGFR is also produced in normal cells, it is overexpressed in a variety of tumor cell lines and has been associated with poor prognosis and reduced survival rate.

Moreover, EGFR activation in tumor cells also plays a role in resistance to chemotherapy and radiation treatment.

Over the past two decades, much effort has been directed at developing anticancer agents which can interfere with EGFR activity.

Now, the most common pharmacologic approaches to EGFR inhibition have been achieved by the developments of monoclonal antibodies and small-molecule inhibitors.

This article is from the free online

Introduction to Translational Research: Connecting Scientists and Medical Doctors

Created by
FutureLearn - Learning For Life

Our purpose is to transform access to education.

We offer a diverse selection of courses from leading universities and cultural institutions from around the world. These are delivered one step at a time, and are accessible on mobile, tablet and desktop, so you can fit learning around your life.

We believe learning should be an enjoyable, social experience, so our courses offer the opportunity to discuss what you’re learning with others as you go, helping you make fresh discoveries and form new ideas.
You can unlock new opportunities with unlimited access to hundreds of online short courses for a year by subscribing to our Unlimited package. Build your knowledge with top universities and organisations.

Learn more about how FutureLearn is transforming access to education